Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.39 |
| ▸ | KMO | O15229 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | METAP2 | P50579 | 2/20 | 0.35 |
| ▸ | METAP1 | P53582 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL198081 | 1.00 | PTGDR2 (0.48) | PTGDR2LMNAMAPK1PTGDRKMO | |
| SCHEMBL30913266 | 1.00 | PTGDR2 (0.48) | PTGDR2LMNAMAPK1PTGDRKMO | |
| SCHEMBL198311 | 1.00 | PTGDR2 (0.48) | PTGDR2LMNAMAPK1PTGDRKMO | |
| Hydrochloric Acid SCHEMBL8869405 | 0.98 | PTGDR2 (0.47) | PTGDR2LMNAMAPK1PTGDRKMO | |
| SCHEMBL415803 | 0.98 | PTGDR2 (0.45) | PTGDR2LMNAMAPK1PTGDRKMO | |
| SCHEMBL2062948 | 0.98 | PTGDR2 (0.45) | PTGDR2LMNAMAPK1PTGDRKMO | |
| SCHEMBL418663 | 0.98 | PTGDR2 (0.45) | PTGDR2LMNAMAPK1PTGDRKMO | |
| SCHEMBL28336946 | 0.85 | PTGDR2 (0.43) | PTGDR2LMNAPTGDRKMOPTGS2 | |
| SCHEMBL7919662 | 0.85 | PTGDR2 (0.43) | PTGDR2KMOKDM4EPTGS2MEN1 | |
| SCHEMBL2062720 | 0.85 | PTGDR2 (0.42) | PTGDR2KDM4EPTGS2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117886690-A | Method for separating 2-cyclohexyl mandelic acid enantiomer by multistage liquid-liquid extraction | 江西中医药大学 | 2024-04-16 | — | — | CN | claimed |
| US-6825378-B2 | TREATING CYCLOHEXYLPHENYL KETONE WITH YLIDE IN ANHYDROUS SOLVENT TO OBTAIN A-CYCLOHEXYLSTYRENE; DIHYDROXYLATION, OXIDATION | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2004-11-30 | — | — | US | claimed |
| US-20040192962-A1 | Process for the synthesis of enantiomerically pure cyclohexylphenyl glycolic acid | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2004-09-30 | — | — | US | claimed |
| CN-117886690-A | Method for separating 2-cyclohexyl mandelic acid enantiomer by multistage liquid-liquid extraction | 江西中医药大学 | 2024-04-16 | — | — | CN | disclosed |
| CN-117886690-A | Method for separating 2-cyclohexyl mandelic acid enantiomer by multistage liquid-liquid extraction | 江西中医药大学 | 2024-04-16 | — | — | CN | disclosed |
| CN-117886690-A | Method for separating 2-cyclohexyl mandelic acid enantiomer by multistage liquid-liquid extraction | 江西中医药大学 | 2024-04-16 | — | — | CN | disclosed |
| EP-2319919-B1 | Nitrilases | BASF ENZYMES LLC (US) | 2015-08-12 | — | — | EP | disclosed |
| US-20110245293-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | ASTRAZENECA AB (SE) | 2011-10-06 | — | — | US | disclosed |
| US-20110207770-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A SECOND ACTIVE INGREDIENT | ASTRAZENECA AB (SE) | 2011-08-25 | — | — | US | disclosed |
| EP-2323655-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A SECOND ACTIVE INGREDIENT | AstraZeneca AB (SE) | 2011-05-25 | — | — | EP | disclosed |
| EP-2323656-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | AstraZeneca AB (SE) | 2011-05-25 | — | — | EP | disclosed |
| US-6140529-A | Synthesis of optically active cyclohexylphenylglycolate esters | SEPRACOR INC. (US) | 2000-10-31 | — | — | US | disclosed |
| EP-0828702-B1 | PROCESS FOR RESOLVING CHIRAL ACIDS WITH 1-AMINOINDAN-2-OLS | SEPRACOR INC (US) | 2000-08-30 | — | — | EP | disclosed |
| US-6090971-A | Resolution process for cyclohexylphenyl glycolic acid | SEPRACOR INC. (US) | 2000-07-18 | — | — | US | disclosed |
| WO-2000023414-A2 | SYNTHESIS OF OPTICALLY ACTIVE CYCLOHEXYLPHENYLGLYCOLIC ACID AND ITS ESTERS | SEPRACOR INC. (US) | 2000-04-27 | — | — | WO | disclosed |
| US-5973182-A | Carbonate Intermediates useful in the preparation of optically active cyclohexylphenylglycolate esters | SEPRACOR INC. (US) | 1999-10-26 | — | — | US | disclosed |
| EP-0828702-A1 | PROCESS FOR RESOLVING CHIRAL ACIDS WITH 1-AMINOINDAN-2-OLS | SEPRACOR, INC. (US) | 1998-03-18 | — | — | EP | disclosed |
| US-5677469-A | PREPARING MIXTURE OF CHIRAL ACID AND ENANTIOMER OF AMINOINDANOL IN SOLVENT, SEPARATING DIASTEREOMERIC SALT, RECOVERING CHIRAL ACID | SEPRACOR, INC. (US) | 1997-10-14 | — | — | US | disclosed |
| WO-1996036584-A1 | PROCESS FOR RESOLVING CHIRAL ACIDS WITH 1-AMINOINDAN-2-OLS | SEPRACOR, INC. (US) | 1996-11-21 | — | — | WO | disclosed |
| US-5036107-A | Treatment of neurogenic bladder disorders | MARION MERRELL DOW INC. (US) | 1991-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245293-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | ADRB2, ADRB1, ADRA2A | PTGDR2 198/4885LMNA 2328/4885MAPK1 2720/4885 |
| US-20110207770-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A SECOND ACTIVE INGREDIENT | GRK5, GRK2, GRK4 | PTGDR2 130/4885LMNA 3904/4885MAPK1 291/4885 |
| US-20040192962-A1 | Process for the synthesis of enantiomerically pure cyclohexylphenyl glycolic acid | GRHPR, PGD, HPD | PTGDR2 2495/4885LMNA 3406/4885MAPK1 481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.